secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001104659-25-057807
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics stockholders elect director slate, ratify auditor, approve say-on-pay at 2025 annual meeting
--------------------------------------------------------------------------------

- All three Class III directors (Jean-Pierre Bizzari, Oren Gilad, John B. Henneman III) elected with >95% of votes cast for.
- Ratification of EisnerAmper LLP as 2025 auditor passed with 2,916,782 for, 49,535 against, 35,669 abstain.
- Non-binding advisory vote on exec compensation approved (1,628,716 for, 58,828 against, 34,829 abstain).
- Say-on-frequency vote: 1 year received 1,159,068 votes; plurality for 1-year frequency.
- Quorum achieved with 3,817,718 shares (69% of shares entitled to vote) represented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465925057807/0001104659-25-057807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465925057807/tm2517510d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-057807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer